{"id":19196,"date":"2020-07-13T15:54:35","date_gmt":"2020-07-13T15:54:35","guid":{"rendered":"http:\/\/www.sinfronterasagencias.com\/?p=19196"},"modified":"2020-07-13T15:54:35","modified_gmt":"2020-07-13T15:54:35","slug":"dan-visto-bueno-a-dos-vacunas-experimentales-contra-el-covid-19","status":"publish","type":"post","link":"https:\/\/www.sinfronterasagencias.com\/?p=19196","title":{"rendered":"DAN VISTO BUENO A DOS VACUNAS EXPERIMENTALES CONTRA EL COVID 19"},"content":{"rendered":"

 <\/p>\n

\"\"<\/a><\/p>\n

*Las candidatas, BNT162b1 y BNT162b2, son las m\u00e1s avanzadas<\/p>\n

Por Agencias SFAS\/Washington, DC.- Dos vacunas experimentales contra el coronavirus desarrolladas conjuntamente por la firma biotecnol\u00f3gica alemana BioNTech y el gigante farmac\u00e9utico estadunidense Pfizer recibieron la designaci\u00f3n de \u00abv\u00eda r\u00e1pida\u00bb por la agencia reguladora de Estados Unidos.<\/p>\n

En un comunicado, las firmas precisaron que las candidatas, BNT162b1 y BNT162b2, son las m\u00e1s avanzadas de entre al menos cuatro vacunas evaluadas por las empresas en ensayos en Estados Unidos y Alemania.<\/p>\n

Si los estudios en marcha son exitosos y el candidato a vacuna recibe la aprobaci\u00f3n regulatoria, las firmas dijeron que esperan poder elaborar hasta 100 millones de dosis para fines de a\u00f1o y, potencialmente, m\u00e1s de mil 200 millones para fines de 2021.<\/p>\n","protected":false},"excerpt":{"rendered":"

  *Las candidatas, BNT162b1 y BNT162b2, son las m\u00e1s avanzadas Por Agencias SFAS\/Washington, DC.- Dos vacunas experimentales contra el coronavirus…<\/p>\n","protected":false},"author":2,"featured_media":19197,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[16,22],"tags":[],"class_list":["post-19196","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-internacional","category-portada-principal"],"_links":{"self":[{"href":"https:\/\/www.sinfronterasagencias.com\/index.php?rest_route=\/wp\/v2\/posts\/19196","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.sinfronterasagencias.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.sinfronterasagencias.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.sinfronterasagencias.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.sinfronterasagencias.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=19196"}],"version-history":[{"count":1,"href":"https:\/\/www.sinfronterasagencias.com\/index.php?rest_route=\/wp\/v2\/posts\/19196\/revisions"}],"predecessor-version":[{"id":19198,"href":"https:\/\/www.sinfronterasagencias.com\/index.php?rest_route=\/wp\/v2\/posts\/19196\/revisions\/19198"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.sinfronterasagencias.com\/index.php?rest_route=\/wp\/v2\/media\/19197"}],"wp:attachment":[{"href":"https:\/\/www.sinfronterasagencias.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=19196"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.sinfronterasagencias.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=19196"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.sinfronterasagencias.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=19196"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}